Literature DB >> 18713330

Cumulative burden of atherosclerotic risk genotypes and the age at onset of a first myocardial infarction: a case-only carriership approach.

Ilan Goldenberg1, Arthur J Moss, Daniel Ryan, Grzegorz Pietrasik, Wojciech Zareba, Scott McNitt, Shirley W Eberly.   

Abstract

BACKGROUND: Previously identified atherosclerotic genetic factors have been studied mostly in case-control studies and in nonuniform ethnic populations, whereas data on the cumulative contribution of genetic factors to an earlier onset of a first myocardial infarction (MI) are limited. We hypothesized that several genetic atherosclerotic single nucleotide polymorphisms (SNPs) may exert an additive effect on the earlier occurrence of coronary atherothrombotic disease after adjustment for clinical factors.
METHODS: Eighteen atherosclerotic high-risk SNPs were selected based upon meta-analyses of 614 published reports, and were incorporated into a carriership model. Multivariate regression analysis was used to identify the independent contribution of selected genotypes to the age at onset of a first MI in a cohort of 814 white (n = 622) and nonwhite (n = 192) patients enrolled in the Thrombogenic Factors and Coronary Events Study.
RESULTS: The analysis demonstrated that selected genotypes were significantly associated with an earlier occurrence of a first MI among white patients (an average of 0.6 year reduction per carried genotype; P = 0.027), whereas the contribution of genotypes to MI onset among nonwhite patients was not significant (an average of 0.7 year increase per carried genotype; P = 0.16), with a significant ethnic x genotype interaction effect (P = 0.02).
CONCLUSIONS: Our findings suggest that currently identified atherosclerotic genetic factors confer an independent additive contribution to the earlier onset of coronary atherothrombotic disease among white patients. The lack of a significant association between these genotypes and outcome in other ethnic groups suggests that cardiovascular genetic risk should be studied directly in these populations.

Entities:  

Mesh:

Year:  2008        PMID: 18713330      PMCID: PMC6931920          DOI: 10.1111/j.1542-474X.2008.00233.x

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  17 in total

1.  The structure of haplotype blocks in the human genome.

Authors:  Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler
Journal:  Science       Date:  2002-05-23       Impact factor: 47.728

2.  Overlap between whites and blacks in response to antihypertensive drugs.

Authors:  Ashwini R Sehgal
Journal:  Hypertension       Date:  2004-02-02       Impact factor: 10.190

3.  Genetic research and health disparities.

Authors:  Pamela Sankar; Mildred K Cho; Celeste M Condit; Linda M Hunt; Barbara Koenig; Patricia Marshall; Sandra Soo-Jin Lee; Paul Spicer
Journal:  JAMA       Date:  2004-06-23       Impact factor: 56.272

4.  'Racial' differences in genetic effects for complex diseases.

Authors:  John P A Ioannidis; Evangelia E Ntzani; Thomas A Trikalinos
Journal:  Nat Genet       Date:  2004-11-14       Impact factor: 38.330

5.  Thrombogenic factors and recurrent coronary events.

Authors:  A J Moss; R E Goldstein; V J Marder; C E Sparks; D Oakes; H Greenberg; H J Weiss; W Zareba; M W Brown; C S Liang; E Lichstein; W C Little; J A Gillespie; L Van Voorhees; R J Krone; M M Bodenheimer; J Hochman; E M Dwyer; R Arora; F I Marcus; L F Watelet; R B Case
Journal:  Circulation       Date:  1999-05-18       Impact factor: 29.690

6.  Smoking and prognosis after acute myocardial infarction in the thrombolytic era (Israeli Thrombolytic National Survey).

Authors:  S Gottlieb; V Boyko; D Zahger; J Balkin; H Hod; B Pelled; S Stern; S Behar
Journal:  J Am Coll Cardiol       Date:  1996-11-15       Impact factor: 24.094

7.  Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction.

Authors:  C L Grines; E J Topol; W W O'Neill; B S George; D Kereiakes; H R Phillips; J D Leimberger; L H Woodlief; R M Califf
Journal:  Circulation       Date:  1995-01-15       Impact factor: 29.690

8.  Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries.

Authors:  G I Barbash; J Reiner; H D White; R G Wilcox; P W Armstrong; Z Sadowski; D Morris; P Aylward; L H Woodlief; E J Topol
Journal:  J Am Coll Cardiol       Date:  1995-11-01       Impact factor: 24.094

9.  Smoking status at the time of acute myocardial infarction and subsequent prognosis.

Authors:  T L Kelly; E Gilpin; S Ahnve; H Henning; J Ross
Journal:  Am Heart J       Date:  1985-09       Impact factor: 4.749

10.  Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators.

Authors:  K L Lee; L H Woodlief; E J Topol; W D Weaver; A Betriu; J Col; M Simoons; P Aylward; F Van de Werf; R M Califf
Journal:  Circulation       Date:  1995-03-15       Impact factor: 29.690

View more
  2 in total

Review 1.  A major role for cardiovascular burden in age-related cognitive decline.

Authors:  Chengxuan Qiu; Laura Fratiglioni
Journal:  Nat Rev Cardiol       Date:  2015-01-13       Impact factor: 32.419

Review 2.  Prophylactic lidocaine for myocardial infarction.

Authors:  Arturo J Martí-Carvajal; Daniel Simancas-Racines; Vidhu Anand; Shrikant Bangdiwala
Journal:  Cochrane Database Syst Rev       Date:  2015-08-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.